Glutathione Supplementation as an Adjunctive Therapy in COVID-19

Related Experiment Video

Updated: Dec 7, 2025

Author Spotlight: Innovating Thiol Quantification and Biomarker Detection for Oxidative Stress Research
03:35

Author Spotlight: Innovating Thiol Quantification and Biomarker Detection for Oxidative Stress Research

Published on: June 28, 2024

1.9K

Vika Guloyan1, Buzand Oganesian1, Nicole Baghdasaryan1

  • 1College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766-1854, USA.

Antioxidants (Basel, Switzerland)
|September 30, 2020
PubMed

Insights

This review explores how glutathione (GSH) may combat severe COVID-19 by reducing harmful inflammation and oxidative stress. Liposomal GSH could be a valuable adjunctive therapy for patients with this respiratory illness.

Area of Science:

  • Immunology
  • Virology
  • Pulmonology

Background:

  • COVID-19 pathogenesis involves severe cytokine storm and hypercoagulable states.
  • Key factors include elevated interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and reduced interferon-α/β (IFN-α/β).
  • These imbalances drive oxidative stress and multi-organ failure.

Purpose of the Study:

  • To review the epidemiology, transmission, and clinical presentation of COVID-19.
  • To focus on the pathogenesis of COVID-19, particularly the role of immune dysregulation.
  • To explore the potential of liposomal glutathione (GSH) as an adjunctive treatment for COVID-19.

Main Methods:

  • Literature review of COVID-19 pathogenesis.
  • Analysis of existing research on glutathione (GSH) in viral infections and pulmonary diseases.
  • Discussion of GSH's proposed mechanisms of action in mitigating COVID-19 pathology.

Main Results:

  • Glutathione (GSH) has demonstrated ability to inhibit viral replication in other diseases.
  • GSH can decrease levels of pro-inflammatory cytokines like IL-6.
  • Evidence suggests GSH benefits other pulmonary conditions, indicating potential for COVID-19.

Conclusions:

  • Liposomal glutathione (GSH) may offer a beneficial adjunctive therapy for COVID-19.
  • GSH could help manage the cytokine storm and oxidative stress associated with severe COVID-19.
  • Further research into liposomal GSH for COVID-19 treatment is warranted.

Keywords:
COVID-19IL-6TNF-αcytokinesglutathione

More Related Videos

The Cell-based L-Glutathione Protection Assays to Study Endocytosis and Recycling of Plasma Membrane Proteins09:22

The Cell-based L-Glutathione Protection Assays to Study Endocytosis and Recycling of Plasma Membrane Proteins

Published on: December 13, 2013

10.8K
Assessment of Glutamine as a Fuel Source for Alveolar Macrophages Exposed to Chronic Ethanol Using an Extracellular Flux Bioanalyzer08:37

Assessment of Glutamine as a Fuel Source for Alveolar Macrophages Exposed to Chronic Ethanol Using an Extracellular Flux Bioanalyzer

Published on: November 15, 2024

601

Related Concept Videos

Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation01:22

Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation

Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
630
Sulfur Assimilation01:20

Sulfur Assimilation

Sulfur is an essential element in biological systems, contributing to synthesizing key biomolecules, including amino acids such as cysteine and methionine, and cofactors such as coenzyme A and biotin. Microorganisms primarily assimilate sulfur as sulfate (SO₄²⁻) from the environment, which must undergo a series of biochemical transformations before it can be incorporated into cellular components. As sulfate is highly oxidized, it must undergo assimilatory sulfate reduction to...
222
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
580
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
335
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.5K
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
201